Abstract
Recent evidence has shown that after the initial occlusion, a large portion of stroke patients achieve some degree of reperfusion either through collateral circulation or clot dissolution. However, it appears that this reperfusion may lead to increased inflammation-induced damage. Even though the exact mechanism of this secondary injury is unclear, several experimental studies have indicated an intimate connection between complement and this secondary form of damage. We review the available literature and attempt to identify promising clinical therapeutic targets.
Keywords: Complement, stroke, reperfusion, ischemia
Current Vascular Pharmacology
Title: The Complement Cascade: New Avenues in Stroke Therapy
Volume: 7 Issue: 3
Author(s): Ricardo J. Komotar, Robert M. Starke, Eric J. Arias, Matthew C. Garrett, Marc L. Otten, Maxwell B. Merkow, Benjamin Hassid, J. Mocco, Michael E. Sughrue, Grace H. Kim, William J. Mack, Andrew F. Ducruet and E. Sander Connolly
Affiliation:
Keywords: Complement, stroke, reperfusion, ischemia
Abstract: Recent evidence has shown that after the initial occlusion, a large portion of stroke patients achieve some degree of reperfusion either through collateral circulation or clot dissolution. However, it appears that this reperfusion may lead to increased inflammation-induced damage. Even though the exact mechanism of this secondary injury is unclear, several experimental studies have indicated an intimate connection between complement and this secondary form of damage. We review the available literature and attempt to identify promising clinical therapeutic targets.
Export Options
About this article
Cite this article as:
Komotar J. Ricardo, Starke M. Robert, Arias J. Eric, Garrett C. Matthew, Otten L. Marc, Merkow B. Maxwell, Hassid Benjamin, Mocco J., Sughrue E. Michael, Kim H. Grace, Mack J. William, Ducruet F. Andrew and Connolly Sander E., The Complement Cascade: New Avenues in Stroke Therapy, Current Vascular Pharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157016109788340677
DOI https://dx.doi.org/10.2174/157016109788340677 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran)
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology The Opioid Receptor Independent Actions of Kappa Receptor Agonists in the Cardiovascular System
Current Pharmaceutical Design The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Percutaneous Pulmonary Valve Implantation: Current Status and Future Perspectives
Current Cardiology Reviews Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Editorial: Effect of Statins on Rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy
Current Vascular Pharmacology